Innate Pharma S.A. (IPHA)
Innate Pharma S.A. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Innate Pharma S.A. (IPHA) is a Biotechnology company based in FR with a market capitalization of $165.7M. Revenue declined 77.9% year-over-year and free cash flow was negative at -$58.1M. This page tracks IPHA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
FR · 181 employees · IPO Oct 17, 2019
Valuation
Valuation & price
$1.76as of May 26, 2026· -25.8% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$165.7M
Market cap
-77.9%
Revenue growth (YoY)
100.0%
Gross margin
-$58.1M
Free cash flow (USD)
-$11.7M
Net debt
Net cash position
10.3%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 6-K filingJul 23, 2026Filing
Conference Participation
- 6-K filingJul 21, 2026Filing
Enrollment Completion Announcement
- 6-K filingMay 22, 2026Filing
Annual General Meeting Results
- 6-K filingMay 19, 2026Filing
Conference Participation
- Quarterly reportMay 13, 2026Filing
Quarterly Report Filed
- 6-K filingMay 12, 2026Filing
Voting Rights Update
- Quarterly reportMay 6, 2026Filing
Quarterly Report Filed
- 6-K filingApr 23, 2026Filing
Investor Conference Participation
- 6-K filingApr 17, 2026Filing
Clinical Trial Results Presentation
- 6-K filingApr 13, 2026Filing
Annual General Meeting Notice
Questions
Frequently asked questions
What is Innate Pharma S.A.'s market cap?
Innate Pharma S.A. (IPHA) has a market capitalization of $165.7M.
What is IPHA's P/E ratio?
A meaningful P/E ratio is not available for IPHA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying IPHA stock?
SEC Form 4 filings show no open-market insider buys at Innate Pharma S.A. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.